Abstracts Archive - Page 69 of 2616 - ACR Meeting Abstracts

Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 0966 • ACR Convergence 2025
Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
kristina clark¹, Xu Shiwen², Xue Li², Voon H. Ong³ and Christopher Denton⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ²University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 0538 • ACR Convergence 2025
Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
Khalid Alnaqbi¹, Jorge Juan Fragío Gil², Hiba Khogali³, Gianina Statache⁴, Alzahraa Abouelnadar⁴, Ahlam Almarzooqi⁵, Amina AlJasmi⁶, Jameel Shawaqfeh⁷, Manal Mashaleh⁸, Maysoon Bani Hani⁷, Saitah Alshammari⁹, Yasser H. Alghamdi⁹, Faisal Alfaisal⁹, Abdulaziz Almosabihi⁹, Cristina Campos Fernández¹⁰, Roxana González Mazario¹⁰, Jose Lozano-Montoya¹¹, Ana Jiménez-Pastor¹¹, Paula Moreno-Ruiz¹¹, Marta Martínez-Calle¹¹, Fuensanta bellvís-Bataller¹¹ and Almudena Fuster-Matanzo¹¹, ¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ²Hospital General Universitario, Valencia, Spain, ³Madinat Zayed Hospital , Al Dhafra hospitals, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Abu Dhabi Stem Cell Centre/Yas Clinic Hospital, Abu Dhabi, United Arab Emirates, ⁵Emirates Health Services, Sharjah, United Arab Emirates, ⁶Emirates Health Services, Dubai, United Arab Emirates, ⁷Royal Medical Services, Amman, Jordan, ⁸Al Saudi Hospital, Amman, Jordan, ⁹King Saud Medical City, Riyadh, Saudi Arabia, ¹⁰Hospital General de Valencia, Valencia, Spain, ¹¹Quibim, Valencia, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated inflammatory disease primarily affecting spine and sacroiliac joints (SIJ), leading to pain and disability. Magnetic resonance imaging…
Abstract Number: 0975 • ACR Convergence 2025
Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Xuezhi Hong¹, Yanhua Xiao², shihao zhu³, Tim Filla⁴, Andrea-Hermina Györfi⁵, Yi-Nan Li⁶, Meilin Xu⁷, Langxian Zhi², Thuong Trinh-Minh⁸, Clara Dees⁹, Georg Schett¹⁰, Jörg Distler¹¹ and Alexandru-Emil Matei¹², ¹Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, Düsseldorf, Germany, ²Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ³Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Düsseldorf, Germany, ⁸Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁹Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a progressive fibrotic disease characterized by fibroblast activation and immune dysregulation, with limited therapeutic options. Mitochondrial dysfunction is increasingly implicated…
Abstract Number: 0656 • ACR Convergence 2025
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Fangfang Sun¹, Huijing Wang¹, Danting Zhang¹, Nan Shen¹, Sheng Chen¹, Tiing Li¹, Weiguo Wan², Shengming Dai³ and Shuang Ye⁴, ¹Renji Hospital, Shanghai, China (People's Republic), ²Huashan Hospital, Shanghai, China (People's Republic), ³Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanized monoclonal antibody belimumab with 10mg/kg was effective for active patients. The efficacy of…
Abstract Number: 0530 • ACR Convergence 2025
Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
Annika Nack¹, Xabier Michelena Vegas², Pol Maymó-Paituvi³, Cristina Calomarde-Gómez⁴, david lobo⁵, Asier García-Alija⁶, Raquel Ugena-García⁴, Maria Aparicio¹, Paola Vidal Montal⁷ and Diego Benavent⁸, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Universitari Vall Hebron, Barcelona, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Doctor Josep Trueta University Hospital, Girona, Catalonia, Spain, ⁶Sant Pau Hospital, Barcelona, Catalonia, Spain, ⁷Bellvitge University Hospital, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, Madrid, Spain
Background/Purpose: Low back pain (LBP) is a multifactorial condition managed by various specialists. AI chatbots like ChatGPT may help clinicians identify probable diagnoses. Given that…
Abstract Number: 0727 • ACR Convergence 2025
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Sehreen Mumtaz¹, Kindalem Fentie², Joseph Parker², Emily Craver¹, Vikas Majithia³ and Andy Abril⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic Hospital, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville
Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
Abstract Number: 0968 • ACR Convergence 2025
Mesenchymal Stromal Cells in Systemic Sclerosis are Dysfunctional and Have a Profibrotic and Senescent Phenotype
Marianela Brizio¹, Benoit Brilland¹, Maximilien Lora², Mathieu Mancini¹, David Langlais¹, Marie Hudson³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Mesenchymal stromal cells (MSCs) are non-hematopoietic multipotent cells with immunomodulatory, proangiogenic, and antifibrotic properties. MSC functions are mediated by paracrine soluble factors and small…
Abstract Number: 0984 • ACR Convergence 2025
Interleukin-21 as a driver of CD8 T cell tissue resident memory and pathogenesis in dermatomyositis
Heather Ren¹, havell Markus², Mackenzie Sennett², Acela Cristina Rosado¹, Matthew Helm¹, Aron Lukacher², Amanda Nelson² and Galen Foulke¹, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine, Hershey, PA
Background/Purpose: Dermatomyositis is an autoimmune disease characterized by skin and muscle pathology and can feature significant morbidity and mortality from interstitial lung disease (ILD). Dermatomyositis…
Abstract Number: 0736 • ACR Convergence 2025
Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
Ana Serrano-Combarro¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Rafael B. Melero-González⁷, Isabel De la Morena⁸, Ivan Ferraz Amaro⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA, VALENCIA, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Stroke is a feared complication of giant cell arteritis (GCA). Tocilizumab (TCZ) has shown efficacy and safety in large-vessel vasculitis (LVV) including GCA. Our…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0993 • ACR Convergence 2025
NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Leah Huey¹, Emily Vance², Bryce Binstadt³ and Ruth Napier², ¹Oregon Health & Science University, Denver, CO, ²University of Colorado Anschutz, Aurora, CO, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Blau syndrome is a pediatric rheumatic disease characterized by dermatitis, arthritis, and uveitis. Blau syndrome is caused by inborn or de novo mutations in…
Abstract Number: 1023 • ACR Convergence 2025
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Margarita Isabel Alarcon-Jarquin¹, Fernanda M. Garcia-Garcia², Vanessa L. Lopez-Flores¹, Aranxa Galindo-Bandt³, Mario A. Arellano-Alvarez³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado² and Janett C. Riega-Torres⁴, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health impairment is common in patients with immune-mediated rheumatic diseases (IMRDs) due to chronic inflammation and immune dysregulation. These complications can worsen systemic…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].